6
Participants
Start Date
April 30, 2008
Primary Completion Date
October 31, 2009
Study Completion Date
October 31, 2009
canakinumab
10 mg/kg intravenous infusion 250 mL over 2 hours.
dexamethasone
12 mg intravenous infusion 50 mL over 30 minutes.
placebo matching canakinumab
5% glucose in water intravenous infusion.
placebo matching dexamethasone
Placebo intravenous infusion.
Novartis Investigator Site, Birmingham
Novartis Investigator Site, New Brunswick
Novartis Investigator Site, Lausanne
Novartis Investigator Site, Glasgow
Lead Sponsor
Novartis
INDUSTRY